Jane Street Group LLC bought a new stake in Acceleron Pharma Inc (NASDAQ:XLRN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 39,137 shares of the biopharmaceutical company’s stock, valued at approximately $1,461,000. Jane Street Group LLC owned approximately 0.09% of Acceleron Pharma at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in XLRN. Westfield Capital Management Co. LP lifted its holdings in Acceleron Pharma by 46.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after purchasing an additional 534,440 shares in the last quarter. Sectoral Asset Management Inc lifted its holdings in Acceleron Pharma by 378.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after purchasing an additional 478,099 shares in the last quarter. BlackRock Inc. lifted its holdings in Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after purchasing an additional 330,635 shares in the last quarter. AXA purchased a new position in Acceleron Pharma in the 2nd quarter valued at about $9,833,000. Finally, UBS Asset Management Americas Inc. purchased a new position in Acceleron Pharma in the 2nd quarter valued at about $9,747,000. Institutional investors own 85.70% of the company’s stock.
A number of research analysts have issued reports on the stock. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Monday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $62.00 price objective on shares of Acceleron Pharma in a research note on Monday, December 11th. Credit Suisse Group set a $51.00 price objective on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. Finally, Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $44.56.
In other Acceleron Pharma news, Director Jean George sold 105,122 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the transaction, the director now owns 1,250 shares in the company, valued at approximately $44,662.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is currently owned by corporate insiders.
Acceleron Pharma Inc (NASDAQ:XLRN) traded up $0.22 on Tuesday, reaching $42.66. 237,128 shares of the company were exchanged, compared to its average volume of 217,150. The firm has a market cap of $1,919.77, a P/E ratio of -16.47 and a beta of 1.59. Acceleron Pharma Inc has a 12-month low of $23.07 and a 12-month high of $43.68.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.55) EPS. equities analysts predict that Acceleron Pharma Inc will post -2.65 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Jane Street Group LLC Buys Shares of 39,137 Acceleron Pharma Inc (XLRN)” was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/03/jane-street-group-llc-purchases-new-holdings-in-acceleron-pharma-inc-xlrn.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.